Biopsy-Proven Esophageal Cancer
Adenocarcinoma or SCC
All Pathways
Upper GI SurgeryDiagnostic
Esophageal Cancer Workup and Staging (NCCN 2024)
Esophageal Cancer Workup and Staging (NCCN 2024): Biopsy-Proven Esophageal Cancer → Staging Workup → Biomarker Testing → Clinical Stage → Superficial.
Pathway Overview
14 steps
Algorithm Steps
14 total
01Start 02Action Staging Workup
CT, PET-CT, EUS
- CT C/A with contrast
- PET-CT (especially SCC)
- EUS for T/N staging
03Action Biomarker Testing
HER2, PD-L1, MSI
- HER2 (adenocarcinoma)
- PD-L1 CPS score
- MSI/dMMR status
04Decision Clinical Stage
- Superficial (Tis-T1a)
- Locoregional (T1b-T4a)
- Locally advanced (T4b)
- Metastatic (M1)
05Action Superficial
Tis-T1a, mucosa only
06Action Endoscopic Therapy
EMR/ESD for Tis-T1a
- Curative if no LVI, clear margins
- Surveillance + Barrett's ablation
07End Surveillance & Support
EGD q3-6mo x2yr, nutrition, follow-up imaging
08Action Esophagectomy
Ivor Lewis, transhiatal, or McKeown
- MIE preferred
- R0 resection goal
- Appropriate for T1b-T4a post-neoadjuvant
- Path rejoins step 07Shared downstream outcome
09Action Locoregional
T1b-T4a, resectable
10Action Neoadjuvant Therapy
CROSS chemoRT or FLOT
- Carboplatin/paclitaxel + 41.4 Gy
- FLOT for GEJ extension
- Path rejoins step 08Shared downstream outcome
- Path rejoins step 08Shared downstream outcome
11Action Locally Advanced/T4b
Unresectable or SCC organ preservation
12Action Definitive ChemoRT
50-50.4 Gy concurrent chemo
- Organ preservation for SCC
- Salvage esophagectomy option
- Path rejoins step 07Shared downstream outcome
13Action Metastatic
M1 disease
14Action Systemic Therapy
Chemo + immunotherapy
- FOLFOX/CAPOX + pembrolizumab
- Trastuzumab if HER2+
- Palliative stent for dysphagia
- Path rejoins step 07Shared downstream outcome
Guideline Source
NCCN Guidelines - Esophageal and GEJ Cancers Version 4.2024
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- GEJ tumors (Siewert I-III) have different classification
- Cervical esophageal cancer typically definitive CRT
- Fitness for esophagectomy requires careful evaluation
Applicable Regions
USAUUKEU
EU: ESMO esophageal cancer guidelines
UK: NICE oesophageal cancer pathway
US: NCCN esophageal guidelines
Version 1Next review: 2028-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Esophageal Cancer Workup and Staging (NCCN 2024)?
The Esophageal Cancer Workup and Staging (NCCN 2024) is a diagnostic clinical algorithm for Upper GI Surgery. It provides a structured decision tree to guide clinical decision-making, based on NCCN Guidelines - Esophageal and GEJ Cancers Version 4.2024.
What guideline is the Esophageal Cancer Workup and Staging (NCCN 2024) based on?
This algorithm is based on NCCN Guidelines - Esophageal and GEJ Cancers Version 4.2024 (DOI: 10.6004/jnccn.2024.0016).
What are the limitations of the Esophageal Cancer Workup and Staging (NCCN 2024)?
Known limitations include: GEJ tumors (Siewert I-III) have different classification; Cervical esophageal cancer typically definitive CRT; Fitness for esophagectomy requires careful evaluation. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Esophageal Cancer Workup and Staging (NCCN 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free